

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: N/A	
Policy Number: PHW.PDL.104	Effective Date: 01/01/2020 Revision Date: 10/2021	
Policy Name: Acne Agents, Topical		
Type of Submission – <u>Check all that apply</u> :		
□ New Policy□ Revised Policy*		
 ✓ Annual Review - No Revisions ✓ Statewide PDL - Select this box when submitting policies f when submitting policies for drug classes included on the S 		
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.		
Please provide any changes or clarifying information for the pol	icy below:	
Q1 2022 annual review: no changes.		
Name of Authorized Individual (Please type or print):	Signature of Authorized Individual:	
Venkateswara R. Davuluri, MD	C-Raulun	
	-	

CLINICAL POLICY Acne Agents, Topical



Clinical Policy: Acne Agents, Topical

Reference Number: PHW.PDL.104

Effective Date: 01/01/2020 Last Review Date: 10/2021

Revision Log

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness[®] that Topical Acne Agents are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Acne Agents, Topical

A. Prescriptions That Require Prior Authorization

Prescriptions for Acne Agents, Topical that meet any of the following conditions must be prior authorized:

- 1. A non-preferred Acne Agent, Topical.
- 2. An Acne Agent, Topical that contains a topical retinoic acid derivative or azelaic acid when prescribed for a beneficiary age 21 years or older.
- 3. An Acne Agent, Topical with a prescribed quantity that exceeds the quantity limit.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Acne Agent, Topical, the determination of whether the requested prescription is medically necessary will take into account the whether the beneficiary:

- 1. For a non-preferred Acne Agent, Topical, has a history of therapeutic failure, contraindication, or intolerance to the preferred Acne Agents, Topical; **AND**
- 2. For specified preferred and non-preferred Acne Agents, Topical listed in Section A.2. when prescribed for a beneficiary age 21 years or older, has a diagnosis that confirms the treatment is for a non-cosmetic indication, such as, but not limited to, acne, rosacea, or plaque psoriasis; **AND**
- 3. If a prescription for an Acne Agent, Topical is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth PA.CP.PMN.59 Quantity Limit Override.



NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Acne Agent, Topical. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. Approval Duration: 12 months

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q1 2022 annual review: no changes.	10/2021